+ All Categories

Home > Documents > Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic...

Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic...

Date post:	18-Jan-2016
Category:	Documents
Upload:	morris-fitzgerald
View:	215 times
Download:	0 times

Download Report this document

Share this document with a friend

Embed Size (px):

Popular Tags:

fortunato ciardiello

asco annual meetingefficacy

asco annual meetingsafety

asco annual meetingbackground

asco annual meetingconclusions

tumor ras mutation status

crystal study patients

folfiri withwithout

21

Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Transcript

Page 1: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 2: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Disclosure Information<br />Relationships Relevant to this Session

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 3: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

CRYSTAL study design

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 4: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Background

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 5: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

RAS mutation analysis: BEAMing

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 6: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

RAS mutation analysis: BEAMing

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 7: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Study profile

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 8: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Other RAS mutations: CRYSTAL

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 9: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Other RAS mutations: first-line studies

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 10: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Comparison of RAS subgroups: <br />efficacy

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 11: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Baseline characteristics

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 12: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Efficacy: RAS subgroups

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 13: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Efficacy: RAS subgroups

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 14: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Progression-free survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 15: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Progression-free survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 16: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Overall survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 17: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Overall survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 18: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Efficacy: RAS subgroups

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 19: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Safety: grade 3/4 adverse events

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 20: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Conclusions

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Page 21: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.

Acknowledgments

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Recommended

MCRC Submission Report

COLORECTAL CANCER RESEARCH & PRACTICE UPDATES · 2020. 5. 11. · bevacizumab among patients with previously untreated metastatic colorectal cancer (mCRC). First -line FOLFOXIRI plus

Company’s · Metastatic Colorectal Cancer (mCRC) patients can be treated with: ̶Conventional Chemotherapy (5 FU, Irinotecan, Oxaliplatin, FolFox, Folfiri) ̶Targeted therapies

Veridex, LLC Metastatic Prostate Cancer K07333Metastatic Prostate Cancer Metastatic Colorectal Cancer (MCRC) A total 1,627 duplicate blood samples were collected from 430 MCRC patients

Defined Health is pleased to present · metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test Bevacizumab, mCRC Doxorubicin liposomal, Kaposi’s

FOLFIRI chemotherapy guide

ThePursuit ofMarginalIndications anda Me·Too …alo.mit.edu/wp-content/uploads/2015/06/Unitended...OS Criteria d Ziv-Aflibercept 6B 8/3/2012 1226 Second-line mCRC; with FOLFIRI 2.2

iDSI Indonesia – Mission Report - globalhitap.net fileJKN Jaminan Kesehatan Nasional, the universal healthcare program mCRC Metastatic Colorectal Cancer MoH Ministry of Health, Indonesia

FOLFOXIRI plus bevacizumab (BV) vs FOLFIRI plus BV as first- line treatment of metastatic colorectal cancer (MCRC): preliminary safety results of the phase.

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer ( mCRC )

Bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized.

Berlin et al. ESMO 2006 Safety and Efficacy of Panitumumab Monotherapy in the Treatment of Metastatic Colorectal Cancer (mCRC) – Summary of Results Across.

ASCO 2010 CONFIDENTIAL DO NOT DISTRIBUTE Randomized, open-label, phase 3 study of panitumumab (pmab) with FOLFIRI vs FOLFIRI alone as 2nd ‑ line treatment.

FOLFOX4 (12 cycles) versus sequential dose-dense FOLFOX7 (6 cycles) followed by FOLFIRI (6 cycles) in patients with initially resectable metastatic colorectal.

XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated overall survival.

ASCO 2012 Effects of Prior Bevacizumab Use on Outcomes From the VELOUR Study: A Phase 3 Study of Aflibercept and FOLFIRI in Patients With Metastatic Colorectal.

Immunotherapy in metastatic colorectal cancer (mCRC ...cpo-media.net/ECP/2019/Congress-Presentations/16/MSI TA Nice.pdf · 3 Bevacizumab Overall Survival) BSC 5-FU 30 Irinotecan

FOLFOXIRI/ bevacizumab ( bev ) versus FOLFIRI/ bev as first-line treatment in unresectable metastatic